Condensed Consolidated Statements of Stockholders' Deficit (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Balance at Dec. 31, 2022		$ 96	$ 5,292,240	$ (7,195,576)	$ (1,903,240)
Balance, shares at Dec. 31, 2022		956,596
Warrants issued to third parties in conjunction with debt issuance			578,016		578,016
Beneficial conversion feature in conjunction with debt issuance			303,984		303,984
Stock based compensation			37,500		37,500
Modification of warrants		$ 11	(15,817)		(15,806)
Modification of warrants, shares		113,525
Fees associated with filing of Form S-1			(5,456)		(5,456)
Net loss				(1,341,036)	(1,341,036)
Balance at Mar. 31, 2023		$ 107	6,190,467	(8,536,612)	(2,346,038)
Balance, shares at Mar. 31, 2023		1,070,121
Balance at Dec. 31, 2022		$ 96	5,292,240	(7,195,576)	(1,903,240)
Balance, shares at Dec. 31, 2022		956,596
Net loss					(2,969,886)
Balance at Sep. 30, 2023		$ 111	6,589,680	(10,165,462)	(3,575,671)
Balance, shares at Sep. 30, 2023	102	1,105,907
Balance at Dec. 31, 2022		$ 96	5,292,240	(7,195,576)	(1,903,240)
Balance, shares at Dec. 31, 2022		956,596
Balance at Dec. 31, 2023		$ 129	7,928,883	(11,341,512)	(3,412,500)
Balance, shares at Dec. 31, 2023	32	1,288,415
Balance at Mar. 31, 2023		$ 107	6,190,467	(8,536,612)	(2,346,038)
Balance, shares at Mar. 31, 2023		1,070,121
Stock based compensation			37,500		37,500
Modification of warrants		$ 16	(208,572)		(208,556)
Modification of warrants, shares		157,228
Net loss				(723,124)	(723,124)
Conversion of common stock for Series A preferred stock		$ (15)	15
Conversion of common stock for Series A preferred stock, shares	30	(152,638)
Common stock issued to third parties in conjunction with conversion of debt		$ 3	197,997		198,000
Common stock issued to third parties in conjunction with conversion of debt, shares		31,075
Balance at Jun. 30, 2023		$ 111	6,217,407	(9,259,736)	(3,042,218)
Balance, shares at Jun. 30, 2023	30	1,105,786
Warrants issued to third parties in conjunction with debt issuance			255,692		255,692
Beneficial conversion feature in conjunction with debt issuance			81,647		81,647
Stock based compensation			37,500		37,500
Modification of warrants		$ 1	(2,567)		(2,566)
Modification of warrants, shares		9,167
Net loss				(905,726)	(905,726)
Conversion of common stock for Series A preferred stock		$ (1)	1
Conversion of common stock for Series A preferred stock, shares	72	(9,045)
Balance at Sep. 30, 2023		$ 111	6,589,680	(10,165,462)	(3,575,671)
Balance, shares at Sep. 30, 2023	102	1,105,907
Balance at Dec. 31, 2023		$ 129	7,928,883	(11,341,512)	(3,412,500)
Balance, shares at Dec. 31, 2023	32	1,288,415
Warrants issued to third parties in conjunction with debt issuance			111,834		111,834
Stock based compensation			37,500		37,500
Net loss				(758,088)	(758,088)
Cancellation of common stock - related party		$ (7)	7
Cancellation of common stock - related party, shares		(64,100)
Post split rounding of shares
Post split rounding of shares, shares		512
Balance at Mar. 31, 2024		$ 122	8,078,224	(12,099,600)	(4,021,254)
Balance, shares at Mar. 31, 2024	32	1,224,827
Balance at Dec. 31, 2023		$ 129	7,928,883	(11,341,512)	(3,412,500)
Balance, shares at Dec. 31, 2023	32	1,288,415
Net loss					(2,817,394)
Balance at Sep. 30, 2024		$ 142	10,236,178	(14,158,906)	(3,922,586)
Balance, shares at Sep. 30, 2024	1,148	1,420,678
Balance at Mar. 31, 2024		$ 122	8,078,224	(12,099,600)	(4,021,254)
Balance, shares at Mar. 31, 2024	32	1,224,827
Warrants issued to third parties in conjunction with debt issuance			99,641		99,641
Stock based compensation			37,500		37,500
Net loss				(862,383)	(862,383)
Common stock issued to third parties in conjunction with conversion of debt		$ 4	232,933		232,937
Common stock issued to third parties in conjunction with conversion of debt, shares		38,826
Preferred stock issued to third parties in conjunction with conversion of debt			841,418		841,418
Preferred stock issued to third parties in conjunction with conversion of debt, shares	1,116
Balance at Jun. 30, 2024		$ 126	9,289,716	(12,961,983)	(3,672,141)
Balance, shares at Jun. 30, 2024	1,148	1,263,653
Warrants issued to third parties in conjunction with debt issuance			179,161		179,161
Stock based compensation			37,500		37,500
Modification of warrants			24,770		24,770
Net loss				(1,196,923)	(1,196,923)
Common stock issued to third parties in conjunction with conversion of debt		$ 12	474,782		474,794
Common stock issued to third parties in conjunction with conversion of debt, shares		118,700
Common stock issued to third party for services		$ 4	214,546		214,550
Common stock issued to third party for services, shares		38,325
Warrants issued to third parties for services			15,703		15,703
Balance at Sep. 30, 2024		$ 142	$ 10,236,178	$ (14,158,906)	$ (3,922,586)
Balance, shares at Sep. 30, 2024	1,148	1,420,678

Sigyn Therapeutics, Inc. 10-Q